.png){kind=logo}
成功案例
How a Korean Biotech Company Secured S$500K for Precision Oncology R&D
RIC helped a Korean biotech group’s Singapore entity secure EDB RISC support to develop a patient-derived organoid platform for precision oncology drug evaluation.
类别
R&D and Innovation
客户类型
Biotechnology / patient-derived organoid platform
授权类型
EDB Research and Innovation Scheme for Companies support
资金已到位
Around S$500,000
关于客户和项目
客户简介
The client is a Korean biotechnology group establishing a Singapore entity to support advanced biomedical R&D and regional growth. Its work focuses on patient-derived organoid technologies that can be used for precision oncology drug evaluation, research collaboration, and pharmaceutical testing. The Singapore entity was positioned as a platform to build local R&D capabilities, hire scientific talent, and anchor high-value biotechnology activity in Singapore.
自然计划
The project involves developing a patient-derived organoid platform for precision oncology drug evaluation in Singapore. The platform is intended to support oncology-focused drug testing and evaluation using organoid-based models, enabling more relevant biological insights for research and therapeutic development.
The project required a multi-year Singapore R&D plan, including local hiring, R&D expenditure, scientific capability building, and supporting equipment or operational costs. The approved RISC conditions required the company to carry out the R&D project in Singapore, incur substantial R&D and innovation expenditure locally, and build a Singapore-based R&D team.
资金目标和挑战
资金目标
The funding objective was to support the client’s Singapore-based R&D capability development under EDB’s Research and Innovation Scheme for Companies. The grant helped support qualifying manpower and project-related costs linked to the development of the patient-derived organoid platform. The broader objective was to anchor meaningful biomedical R&D activity in Singapore, create R&D and innovation roles, build local scientific capability, and strengthen Singapore’s position as a base for precision oncology innovation.
挑战
The client was establishing Singapore as a base for advanced biotechnology R&D, with a project focused on developing a patient-derived organoid platform for precision oncology drug evaluation. While the parent group had established capabilities overseas, the Singapore entity was still relatively new and needed to show EDB that the proposed project would create meaningful local R&D activity, build Singapore-based scientific capability, and generate credible economic value.
The challenge was not simply to write a grant application. The case required careful structuring around EDB’s expectations, including Singapore-based R&D expenditure, qualifying manpower, local hiring, salary thresholds, and headquarters commitment. The client initially had a more conservative hiring plan, including salary levels that would not have aligned well with RISC requirements. RIC had to help the client reshape the project so the Singapore entity could credibly meet EDB’s conditions while still remaining commercially practical for the group.
A further complexity was the need for parent company comfort. Because the Singapore entity was relatively small, EDB required assurance that the overseas parent would support the project financially. This required internal alignment with the client’s corporate headquarters and legal team, so that they understood the grant commitments, risks, obligations, and rationale for supporting the Singapore project.
RIC如何为客户提供支持
RIC provided end-to-end RISC advisory support, with a focus on project structuring, EDB alignment, headquarters buy-in, and grant approval readiness.
RIC’s support included:
• Positioning the project as a Singapore-based R&D and innovation initiative under EDB’s Research and Innovation Scheme for Companies.
• Helping the client articulate the strategic value of building a patient-derived organoid platform in Singapore for precision oncology drug evaluation.
• Translating the technical and commercial project into a grant-ready structure aligned with EDB’s expectations for R&D activity, local capability building, and Singapore economic value.
• Advising the client on the hiring plan, including how to scope R&D roles so they aligned with EDB’s definition of R&D and innovation employees.
• Working with the client to adjust salary levels so the proposed roles could meet EDB’s qualifying manpower requirements, including the S$5,000 monthly salary threshold.
• Supporting the give-and-take discussion with EDB on manpower assumptions, role design, and salary positioning, so the staffing plan remained acceptable without becoming commercially unrealistic.
• Reviewing the client’s cost structure carefully to identify which expenditure could reasonably be incurred in Singapore and counted toward Singapore-based activity.
• Helping the client structure its Singapore spend to support the Total Business Expenditure case and make the project easier to defend during approval and future reporting.
• Supporting the Singapore team in presenting the grant case internally to its Korean headquarters.
• Helping explain to headquarters what EDB was funding, what commitments the Singapore entity had to meet, why the project mattered, and why parent support was required.
• Advising the Singapore point of contact through multiple rounds of internal legal and HQ review, including questions on legal exposure, grant obligations, and consequences if commitments were not fulfilled.
• Helping the client secure headquarters comfort and sign-off for the required support letter so the RISC grant could proceed.
RIC’s role was to bridge the gap between a promising biotech R&D project and the practical realities of EDB approval, including manpower design, Singapore expenditure strategy, and parent-company assurance.
结果
资金已到位
Around S$500,000
The client secured around S$500,000 in EDB RISC support for a Singapore-based R&D project relating to the “Development of the Next & Bio Patient-Derived Organoid Platform for Precision Oncology Drug Evaluation.”
The approved project runs for 3 years, and requires the client to carry out the specified R&D and innovation project in Singapore, incur at least S$750,000 in R&D and innovation expenditure in Singapore, and employ at least 7 R&D and innovation employees based in Singapore by the relevant milestone date.
The win was significant because it validated Singapore as a credible R&D base for the client’s regional biotech ambitions. It also demonstrated RIC’s ability to support sophisticated EDB incentive work beyond proposal writing, including grant structuring, manpower planning, qualifying cost strategy, EDB-facing discussion, and headquarters-level stakeholder alignment.
这对类似公司意味着什么
This case is a strong example of how foreign biotech and deep-tech companies can use Singapore as a serious R&D base when the project is structured correctly. For RISC, the application is not just about whether the technology is innovative. EDB also needs to see credible Singapore-based hiring, qualifying expenditure, local capability building, and parent-company commitment where the applicant entity is new or relatively small.
For foreign companies, one of the hardest parts is often internal alignment. Headquarters may support the expansion in principle but hesitate when asked to sign comfort letters or commit funding to a Singapore subsidiary. This case shows where RIC can add value: helping the local team explain the grant logic to headquarters, clarify the obligations, manage legal concerns, and secure the internal approvals needed for the project to proceed.
For RIC, this is a flagship RISC win because it demonstrates our role as a strategic advisor between the client, EDB, and the overseas parent group. The value was not only in preparing the grant submission. It was in shaping the hiring plan, adjusting salary assumptions, structuring Singapore spend, aligning with EDB’s requirements, and helping headquarters become comfortable enough to back the Singapore R&D project.
